| 0 (0%) | 01-19 18:52 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.97 | 1-year : | 3.45 |
| Resists | First : | 2.54 | Second : | 2.96 |
| Pivot price | 2.23 |
|||
| Supports | First : | 1.87 | Second : | 1.56 |
| MAs | MA(5) : | 1.98 |
MA(20) : | 2.22 |
| MA(100) : | 2.61 |
MA(250) : | 3.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 9.7  |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 7.42 | Low : | 1.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALRN ] has closed above bottom band by 25.5%. Bollinger Bands are 10.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.09 - 2.1 | 2.1 - 2.11 |
| Low: | 1.94 - 1.95 | 1.95 - 1.96 |
| Close: | 1.97 - 1.99 | 1.99 - 2.01 |
Thu, 16 Jan 2025
Aileron straps in for 2025 with a new name: Rein Therapeutics - Fierce Pharma
Tue, 26 Nov 2024
Antimicrobial Resistance Laboratory Network | ARLN - Centers for Disease Control and Prevention | CDC (.gov)
Thu, 14 Nov 2024
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PR Newswire
Fri, 12 Jan 2024
Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists - Nature
Fri, 10 Mar 2023
Early signals in Aileron Therapeutic's ALRN-6924 program hinted at a struggle for efficacy over a year before negative results - statnews.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 22 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 28.4 (%) |
| Shares Short | 233 (K) |
| Shares Short P.Month | 298 (K) |
| EPS | -2.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.9 % |
| Return on Equity (ttm) | -44.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.7 |
| PEG Ratio | 0 |
| Price to Book value | 1.41 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|